REG - Indivior PLC - Joseph Ciaffoni Appointed Chief Executive Officer

IndiviorAnnouncement

27/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250227:nRSa6154Ya&default-theme=true

RNS Number : 6154Y  Indivior PLC  27 February 2025

 

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN
THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018)

Indivior PLC has appointed Joe Ciaffoni, currently an Independent
Non-Executive Director of the Company, as Chief Executive Officer. The terms
of his appointment are subject to, and effective upon, the approval by
shareholders of a new remuneration policy at the Company's AGM in May 2025.

Mr. Ciaffoni, 53, was appointed as an Independent Non-Executive Director to
Indivior's Board in December 2024. He is a proven public company CEO with more
than 30 years of experience in pharmaceuticals and biotech, working in both
global and US organizations. He has a strong track record of operational and
strategic success, working across diverse models and therapeutic areas
spanning specialty, rare disease, mass market and hospital. He most recently
served as President and CEO of Collegium Pharmaceutical and has held senior
roles as Endo International, Biogen and Shionogi Inc.

By mutual agreement, Mark Crossley will be stepping down as Chief Executive
Officer and as a Board Director following a distinguished tenure leading the
Company. Mark will remain with Indivior to support the transition, ensuring
stability and continuity for the business, and is expected to remain as CEO
until at least the date of the Company's AGM in May 2025.

David Wheadon, Chair of Indivior's Board of Directors, said: "We are delighted
to appoint Joe as our next Chief Executive Officer. He is an accomplished
leader with a strong track record of delivering positive outcomes for patients
while generating shareholder value. He has a clear mandate to fuel the next
stage of Indivior's growth and deliver on the Company's significant potential
and we look forward to supporting his success as CEO."

Joe Ciaffoni said: "It is an honor to be appointed as CEO of Indivior is a
leader in the addiction treatment space and its work has never been more
necessary. I look forward to working with the team to deliver on the Company's
potential and to drive Indivior's future growth for the benefit of all our
stakeholders".

Mark was appointed as CEO in June 2020. Under his stewardship, the Company has
strengthened its commitment to patients, expanded access to treatment, and
advanced its mission of pioneering life-transforming treatments for substance
use disorders.

David Wheadon said: "On behalf of the Board of Directors, I would like to
thank Mark for his many contributions to Indivior and wish him the best in his
future endeavors. His integrity and commitment to our patients and the people
of Indivior will leave a lasting impact."

Mark Crossley said: "It has been a tremendous privilege to have worked at
Indivior over the last decade, the last five as CEO. I truly believe in our
vision and commitment to helping our patients and widening access to
treatment, a belief I know is shared by the many incredible colleagues across
the business. I am proud of the pivotal role Indivior plays in combatting one
of the great human crises of our lifetime and I wish the business every
success going forward."

The person responsible for making this announcement is Kathryn Hudson, Company
Secretary.

 

For Further Information

 Investor Enquiries  Jason Thompson  VP, Investor Relations                     +1 804 402 7123

                                     Indivior PLC                               jason.thompson@indivior.com (mailto:jason.thompson@indivior.com)

                     Tim Owens       Director, Investor Relations Indivior PLC  +1 804 263 3978

                                                                                timothy.owens@indivior.com (mailto:timothy.owens@indivior.com)

 Media Enquiries     Jonathan Sibun  Teneo                                      +44 (0)20 7353 4200

                                                                                Indivior@teneo.com (mailto:Indivior@teneo.com)

                                     U.S. Media Inquiries                       +1 804 594 0836

                                                                                Indiviormediacontacts@indivior.com

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD). Our
vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of SUD. Indivior is dedicated to transforming SUD from a global human crisis
to a recognized and treated chronic disease. Building on its global portfolio
of OUD treatments, Indivior has a pipeline of product candidates designed to
expand on its heritage in this category. Headquartered in the
United States in Richmond, VA, Indivior employs over 1,000 individuals
globally and its portfolio of products is available in over 30 countries
worldwide. Visit www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/company/indivior.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUNSRRVVUUUUR